Hep C Treatment Triumph Drives Broader Focus for ILC 2017
Damian McNamara
| April 11, 2017
The congress this year is diverse, and "not dominated as it used to be by viral hepatitis," said Dr Castera. "This is related to the fact that with the new direct-acting antivirals we can cure most patients."
In fact, "we are very close to a 95% cure rate," he reported. However, some areas of unmet need persist — including people with genotype 3 hepatitis C and cirrhosis, nonresponders, and those on waiting lists for liver transplantation — and these will be addressed.
"Because of the high cost of treatment, access is still an issue," Dr Castera pointed out. However, "the field is moving to address access to treatment." One presentation will look at heterogeneous access to direct-acting antiviral therapy in different countries.
The ideal follow-up of patients successfully treated for hepatitis C will also be discussed, Dr Castera said.
Continue reading...
In fact, "we are very close to a 95% cure rate," he reported. However, some areas of unmet need persist — including people with genotype 3 hepatitis C and cirrhosis, nonresponders, and those on waiting lists for liver transplantation — and these will be addressed.
"Because of the high cost of treatment, access is still an issue," Dr Castera pointed out. However, "the field is moving to address access to treatment." One presentation will look at heterogeneous access to direct-acting antiviral therapy in different countries.
The ideal follow-up of patients successfully treated for hepatitis C will also be discussed, Dr Castera said.
Continue reading...
No comments:
Post a Comment